A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

Status:
Recruiting

Trial end date:
2026-02-13

Target enrollment:

Participant gender:

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.

Phase 3

Janssen Research & Development, LLC

Antibodies, Monoclonal